This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): QSC001, orally disintegrating hydrocodone and acetaminophen
Description: QSC-001 is a orally disintegrating tablet (ODT) formulation of hydrocodone bitartrate and acetaminophen (HB/APAP), utilizing Eurand's proprietary Microcaps taste-masking and AdvaTab ODT technologies.
QSC-001 was formulated for Questcor by Eurand. Questcor owns the world-wide rights to commercialize QSC-001 and Eurand will exclusively supply the product and receive a royalty on product sales.
Eurand and Axcan
In December 2010, Eurand and Axcan entered into a definitive agreement under which Axcan will acquire all the outstanding shares of Eurand for $12.00 per share in cash. The fully diluted equity value of the transaction is approximately $583 million. The transaction closed in February 2011.
Aptalis and Forest
In January 2014, Aptalis announced that it has signed a definitive agreement to be acquired by Forest Laboratories. Forest intends to acquire Aptalis from its shareholders for $2.9 billion in cash, pending required reviews by anti-trust authorities in the US and Canada. Forest expects to use a combination of cash on hand and debt to fund the transaction.
In February 2014, Forest Laboratories announced the completion of its...See full deal structure in Biomedtracker
Partners: Allergan plc
Additional information available to subscribers only: